This technology represents a major leap forward in Mass Spectrometry, enabling high-throughput, high-sensitivity analysis that accelerates proteomic research and biomarker discovery.
We can support researchers, biotech innovators, and pharma partners in gaining deeper insights into complex biological systems.
We are the first UK-based commercial organisation to provide services using the Orbitrap Astral Mass Spectrometer to the drug discovery community, enabling precision medicine at scale with next-generation methods for plasma proteomics.
With this platform, we are enabling researchers, biotechs, and translational teams worldwide access to this powerful new technology, which dramatically improves the scale, sensitivity, and speed of proteomic analysis.
“We are a team of Mass Spectrometry researchers with complementary backgrounds spanning organic and analytical chemistry, drug discovery, technology development, physics, cell and molecular biology, cancer research and bioinformatics.
We have established a high-end research laboratory, strategic partnerships, and developed new methods to help tackle a variety of analytical challenges faced by the UK medicines discovery community.
Come and speak to us, and see if we can help.”
Dr Bruno Bellina, Lead Scientist
We will help you to generate high-quality, decision-driving data, whether you are exploring for novel biomarkers, target engagement, or biodistribution.
Fill in the form today and speak to us to see how we can help advance your drug discovery project.